Idasanutlin Active in Refractory Polycythemia Vera

More data out of the 2017 American Society of Hematology Annual Meeting shows that the MDM2 antagonist idasanutlin is well tolerated and demonstrates clinical activity among patients with refractory polycythemia vera.

HemOncToday